AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
prednisone and prednisolone derivatives	4451	125-02-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prednisolone sodium phosphate sodium prednisolone phosphate prednisolone phosphoric acid prednisolone phosphate	Molecular weight: 440.43 Formula: C21H29O8P CLOGP: -0.05 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 141.36 ALOGS: -3.01 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prednisolone sodium phosphate
sodium prednisolone phosphate
prednisolone phosphoric acid
prednisolone phosphate

Molecular weight: 440.43
Formula: C21H29O8P
CLOGP: -0.05
LIPINSKI: 0
HAC: 8
HDO: 4
TPSA: 141.36
ALOGS: -3.01
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	82 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	0.22 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PLK1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	50
kinase-selectivity-class	AXL,BRAF,CDK4,CDK9,EPHB4,ERBB2,GRK2,MAP2K6,MAP3K14,PIK3CD,SYK,TEK,TGFBR1,ZAP70	14
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	0.287		Moderate	0.77
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		Moderate	0.77
rat-kpuu-brain	Rat brain Kpuu	0.002	%	Moderate	0.77

Approvals:

Date	Agency	Company	Orphan
Dec. 19, 1973	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatitis B reactivation	269.99	23.18	64	7914	3910	90616559
Acute hepatic failure	129.83	23.18	55	7923	22506	90597963
Asthma	105.83	23.18	118	7860	242042	90378427
Neurologic neglect syndrome	102.86	23.18	36	7942	8811	90611658
Carotid artery thrombosis	98.11	23.18	35	7943	9057	90611412
Adjustment disorder	96.10	23.18	35	7943	9607	90610862
Personality disorder	90.90	23.18	36	7942	12408	90608061
Gangrene	89.71	23.18	36	7942	12840	90607629
Temperature regulation disorder	88.74	23.18	37	7941	14542	90605927
Bedridden	88.23	23.18	35	7943	12113	90608356
Arterial occlusive disease	87.41	23.18	35	7943	12411	90608058
Hemiplegia	85.07	23.18	37	7941	16123	90604346
Foetal death	82.35	23.18	39	7939	20684	90599785
Angina pectoris	81.99	23.18	48	7930	39112	90581357
Sensory loss	77.95	23.18	36	7942	18039	90602430
Motor dysfunction	75.82	23.18	36	7942	19194	90601275
Affect lability	74.87	23.18	35	7943	18028	90602441
Coordination abnormal	72.24	23.18	36	7942	21320	90599149
Skin haemorrhage	72.20	23.18	36	7942	21344	90599125
Food allergy	71.86	23.18	38	7940	25440	90595029
Psoriasis	69.65	23.18	75	7903	147679	90472790
Hemiparesis	66.59	23.18	39	7939	31780	90588689
Foot fracture	64.78	23.18	36	7942	26570	90593899
Rhinorrhoea	64.48	23.18	57	7921	88259	90532210
Sinus congestion	63.76	23.18	36	7942	27388	90593081
Respiratory tract congestion	61.09	23.18	35	7943	27375	90593094
Sneezing	60.90	23.18	36	7942	29833	90590636
Muscle spasticity	60.31	23.18	38	7940	35284	90585185
Eating disorder	57.67	23.18	34	7944	28039	90592430
Sinus disorder	56.17	23.18	36	7942	34411	90586058
Immunodeficiency	55.64	23.18	39	7939	43195	90577274
Coeliac disease	54.54	23.18	39	7939	44571	90575898
Wheezing	52.44	23.18	83	7895	237997	90382472
Lower limb fracture	50.67	23.18	49	7929	84964	90535505
Heart sounds	50.30	23.18	13	7965	1131	90619338
Prolonged expiration	49.08	23.18	13	7965	1244	90619225
Aphasia	46.83	23.18	35	7943	42777	90577692
Upper respiratory tract infection	46.69	23.18	57	7921	128261	90492208
Immobile	44.94	23.18	18	7960	6380	90614089
Hyponatraemic seizure	44.11	23.18	10	7968	500	90619969
Oedema	41.58	23.18	68	7910	200227	90420242
Dysarthria	41.42	23.18	36	7942	54446	90566023
Enterococcal sepsis	41.37	23.18	12	7966	1604	90618865
Keratopathy	40.85	23.18	10	7968	698	90619771
Cataract	40.06	23.18	40	7938	72052	90548417
Influenza	39.93	23.18	55	7923	139209	90481260
Prescribed overdose	39.85	23.18	46	7932	97579	90522890
Treatment failure	39.07	23.18	84	7894	303844	90316625
Rash erythematous	37.80	23.18	37	7941	65067	90555402
Chest discomfort	37.22	23.18	53	7925	138312	90482157
Skin exfoliation	36.48	23.18	37	7941	67876	90552593
Tonsillar disorder	35.60	23.18	10	7968	1192	90619277
Cystitis	35.20	23.18	36	7942	66682	90553787
Fluid retention	35.10	23.18	41	7937	88050	90532419
Nasal oedema	34.40	23.18	15	7963	6569	90613900
Osteoporosis	33.68	23.18	42	7936	96489	90523980
Loss of personal independence in daily activities	33.51	23.18	50	7928	136055	90484414
Pyrexia	32.26	23.18	129	7849	660356	89960113
Respiration abnormal	31.66	23.18	15	7963	7948	90612521
Drug hypersensitivity	31.56	23.18	101	7877	463508	90156961
Meningitis cryptococcal	31.44	23.18	10	7968	1823	90618646
Influenza like illness	31.25	23.18	37	7941	80574	90539895
Depressive symptom	30.77	23.18	13	7965	5272	90615197
Rheumatoid arthritis	28.40	23.18	83	7895	362531	90257938
Respiratory tract infection	27.81	23.18	30	7948	59048	90561421
Bursitis	27.71	23.18	45	7933	131609	90488860
Oesophageal disorder	27.59	23.18	10	7968	2703	90617766
Appetite disorder	26.82	23.18	14	7964	9119	90611350
Intentional product misuse	26.59	23.18	36	7942	89568	90530901
Cough	26.58	23.18	82	7896	368880	90251589
Fracture	26.28	23.18	19	7959	22057	90598412
Vomiting	25.87	23.18	137	7841	788156	89832313
Hyperhidrosis	25.24	23.18	44	7934	136261	90484208
Osteonecrosis	23.36	23.18	19	7959	26222	90594247

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Choroiditis	262.74	28.76	48	2276	1327	42617684
Intraocular pressure increased	208.87	28.76	52	2272	6381	42612630
Endophthalmitis	196.13	28.76	46	2278	4387	42614624
Uveitis	176.21	28.76	49	2275	9209	42609802
Visual acuity reduced	153.27	28.76	51	2273	17499	42601512
Eye pain	146.76	28.76	49	2275	16981	42602030
Hypersensitivity	73.79	28.76	47	2277	72323	42546688
Condition aggravated	73.37	28.76	80	2244	260674	42358337
Cardiac disorder	57.98	28.76	35	2289	48897	42570114
Total lung capacity abnormal	35.10	28.76	12	2312	4431	42614580
Product use issue	33.42	28.76	30	2294	76721	42542290
Spirometry abnormal	33.38	28.76	12	2312	5134	42613877
Meningomyelitis herpes	33.33	28.76	5	2319	38	42618973
Pulmonary vasculitis	31.08	28.76	12	2312	6254	42612757
Hepatitis B reactivation	30.92	28.76	11	2313	4567	42614444
Steroid dependence	30.26	28.76	12	2312	6710	42612301
Nocardiosis	29.57	28.76	11	2313	5179	42613832

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Choroiditis	224.50	20.76	47	9982	1568	110577702
Intraocular pressure increased	159.28	20.76	53	9976	10823	110568447
Endophthalmitis	144.66	20.76	46	9983	8141	110571129
Asthma	111.48	20.76	125	9904	250166	110329104
Uveitis	110.58	20.76	49	9980	21661	110557609
Visual acuity reduced	106.63	20.76	54	9975	32119	110547151
Neurologic neglect syndrome	100.05	20.76	36	9993	9262	110570008
Carotid artery thrombosis	95.08	20.76	35	9994	9603	110569667
Adjustment disorder	91.22	20.76	35	9994	10760	110568510
Temperature regulation disorder	88.79	20.76	36	9993	12790	110566480
Personality disorder	88.76	20.76	36	9993	12801	110566469
Foetal death	84.25	20.76	37	9992	16008	110563262
Gangrene	80.39	20.76	36	9993	16305	110562965
Arterial occlusive disease	79.40	20.76	35	9994	15273	110563997
Eye pain	76.98	20.76	51	9978	50048	110529222
Food allergy	76.54	20.76	37	9992	19911	110559359
Chorioretinopathy	76.13	20.76	21	10008	2274	110576996
Affect lability	72.81	20.76	35	9994	18602	110560668
Hemiplegia	71.88	20.76	37	9992	22745	110556525
Sensory loss	71.05	20.76	36	9993	21421	110557849
Angina pectoris	69.18	20.76	52	9977	62243	110517027
Coordination abnormal	68.33	20.76	37	9992	25191	110554079
Psoriasis	67.57	20.76	73	9956	139920	110439350
Motor dysfunction	66.68	20.76	36	9993	24370	110554900
Skin haemorrhage	66.10	20.76	36	9993	24791	110554479
Wheezing	61.14	20.76	94	9935	255136	110324134
Bedridden	61.05	20.76	28	10001	13397	110565873
Immunodeficiency	60.78	20.76	40	9989	38798	110540472
Sinus congestion	59.25	20.76	36	9993	30423	110548847
Muscle spasticity	58.68	20.76	38	9991	35877	110543393
Sneezing	57.63	20.76	36	9993	31948	110547322
Sinus disorder	56.87	20.76	36	9993	32692	110546578
Respiratory tract congestion	56.27	20.76	35	9994	30822	110548448
Rhinorrhoea	55.70	20.76	57	9972	102609	110476661
Hepatitis B reactivation	55.23	20.76	22	10007	7462	110571808
Hemiparesis	54.04	20.76	39	9990	43864	110535406
Eating disorder	53.76	20.76	34	9995	30824	110548446
Coeliac disease	52.33	20.76	38	9991	43149	110536121
Heart sounds	49.92	20.76	13	10016	1130	110578140
Skin exfoliation	46.34	20.76	48	9981	87603	110491667
Prolonged expiration	45.98	20.76	13	10016	1539	110577731
Foot fracture	44.13	20.76	28	10001	25518	110553752
Upper respiratory tract infection	42.70	20.76	56	9973	131272	110447998
Aphasia	41.90	20.76	38	9991	58959	110520311
Prescribed overdose	41.06	20.76	45	9984	87536	110491734
Product use issue	40.38	20.76	88	9941	311607	110267663
Oedema	40.30	20.76	70	9959	209906	110369364
Hyponatraemic seizure	40.13	20.76	10	10019	729	110578541
Lower limb fracture	39.36	20.76	41	9988	75307	110503963
Osteonecrosis	39.31	20.76	29	10000	33712	110545558
Keratopathy	38.42	20.76	11	10018	1362	110577908
Cataract	37.54	20.76	41	9988	79444	110499826
Rheumatoid arthritis	37.01	20.76	83	9946	299530	110279740
Loss of personal independence in daily activities	35.52	20.76	55	9974	149965	110429305
Cystitis	34.61	20.76	36	9993	66000	110513270
Respiration abnormal	34.06	20.76	17	10012	9792	110569478
Nasal oedema	33.42	20.76	15	10014	6824	110572446
Hypersensitivity	33.29	20.76	96	9933	403902	110175368
Tonsillar disorder	33.19	20.76	10	10019	1479	110577791
Enterococcal sepsis	32.56	20.76	12	10017	3300	110575970
Acute kidney injury	32.03	20.76	9	10020	635421	109943849
Arthritis	31.02	20.76	55	9974	167531	110411739
Influenza	30.66	20.76	55	9974	169046	110410224
Fluid retention	30.31	20.76	40	9989	94267	110485003
Chest discomfort	29.57	20.76	55	9974	173793	110405477
Post transplant lymphoproliferative disorder	29.20	20.76	18	10011	15595	110563675
Drug hypersensitivity	29.19	20.76	99	9930	453991	110125279
Total lung capacity abnormal	28.78	20.76	12	10017	4571	110574699
Cardiac disorder	28.70	20.76	35	9994	76245	110503025
Rash erythematous	28.31	20.76	36	9993	81796	110497474
Pulmonary vasculitis	27.70	20.76	13	10016	6547	110572723
Influenza like illness	27.64	20.76	37	9992	88375	110490895
Dysarthria	27.53	20.76	36	9993	84085	110495185
Drug interaction	27.30	20.76	6	10023	500177	110079093
Meningomyelitis herpes	26.93	20.76	5	10024	88	110579182
Spirometry abnormal	26.68	20.76	12	10017	5485	110573785
Pyrexia	26.45	20.76	155	9874	898110	109681160
Oesophageal disorder	26.10	20.76	10	10019	3060	110576210
Bursitis	25.81	20.76	44	9985	129874	110449396
Toxicity to various agents	25.75	20.76	6	10023	480549	110098721
Immobile	25.72	20.76	13	10016	7689	110571581
Appetite disorder	25.54	20.76	14	10015	9755	110569515
Osteoporosis	25.02	20.76	35	9994	87117	110492153
Sleep disorder due to a general medical condition	24.81	20.76	27	10002	52085	110527185
Depressive symptom	24.63	20.76	13	10016	8401	110570869
Respiratory tract infection	23.98	20.76	31	9998	71586	110507684
Diarrhoea	23.71	20.76	42	9987	1139463	109439807
Anaemia	23.68	20.76	10	10019	547076	110032194
Palpitations	22.96	20.76	47	9982	159165	110420105
Death	22.82	20.76	18	10011	698851	109880419
Dolichocolon	22.75	20.76	4	10025	51	110579219
Hypotension	21.99	20.76	10	10019	523839	110055431
Pneumocystis jirovecii pneumonia	21.85	20.76	23	10006	42712	110536558
Steroid dependence	21.76	20.76	12	10017	8457	110570813
Condition aggravated	21.72	20.76	127	9902	734709	109844561
Dizziness	21.55	20.76	19	10010	698174	109881096
Strongyloidiasis	21.42	20.76	10	10019	4976	110574294

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:33231	antitubercular agent
CHEBI has role	CHEBI:33281	antimicrobial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35472	anti-inflammatory drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:35816	leprostatic drug
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:37962	adrenergic agent
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:49103	drug metabolite
CHEBI has role	CHEBI:49201	anti-ulcer drug
CHEBI has role	CHEBI:50177	dermatologic drug
CHEBI has role	CHEBI:50671	antithyroid drug
CHEBI has role	CHEBI:50748	antipsoriatic
CHEBI has role	CHEBI:53784	antispasmodic drug
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:75835	anti-anaemic agent
CHEBI has role	CHEBI:76595	nephroprotective agent
CHEBI has role	CHEBI:77715	nasal decongestant
CHEBI has role	CHEBI:78298	environmental contaminant
CHEBI has role	CHEBI:231911	renoprotective agent
CHEBI has role	CHEBI:233423	antifibrotic agent
CHEBI has role	CHEBI:50266	prodrug
CHEBI has role	CHEBI:50857	anti-allergic agent
CHEBI has role	CHEBI:63562	glucocorticoid receptor agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Blepharoconjunctivitis	indication	68659002	DOID:2456
Iridocyclitis	indication	77971008
Bacterial conjunctivitis	indication	128350005	DOID:9700
Uveitis	indication	128473001	DOID:13141
Infective blepharitis	indication	312219000
Superficial Ocular Infection	indication
Ocular hypertension	contraindication	4210003	DOID:9282
Herpes simplex keratitis	contraindication	9389005
Herpes simplex dendritic keratitis	contraindication	29943008
Fungal infection of eye	contraindication	31194008
Severe myopia	contraindication	34187009
Tuberculosis of eye	contraindication	49107007
Diabetes mellitus	contraindication	73211009	DOID:9351
Open-angle glaucoma	contraindication	84494001	DOID:1067
Krukenberg spindle	contraindication	85430004
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Eye infection	contraindication	128351009
Bacterial infection of eye	contraindication	128984004
Viral eye infection	contraindication	312132001
Vaccinia keratitis	contraindication	397552005
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye, such as those associated with allergic reactions or gross irritants	Indication
Dogs	Superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye, such as those associated with allergic reactions or gross irritants	Indication
Dogs	Treatment when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Hydeltrone Ointment	Boehringer lngelheim Animal Health USA Inc.	2
Prednis-A-Vet Injection	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.75	acidic
pKa2	6.8	acidic
pKa3	12.78	acidic
pKa4	13.76	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D00981	KEGG_DRUG
4017987	VUID
N0000146333	NUI
4017987	VANDF
4017988	VANDF
CHEBI:8379	CHEBI
TUA	PDB_CHEM_ID
CHEMBL1201014	ChEMBL_ID
C009022	MESH_SUPPLEMENTAL_RECORD_UI
IV021NXA9J	UNII
441409	PUBCHEM_CID
DB14631	DRUGBANK_ID
34374	RXNORM
16516	MMSL
37825	MMSL
44390	MMSL
5347	MMSL
5349	MMSL
59710	MMSL
d00084	MMSL
002155	NDDF
002157	NDDF
116601002	SNOMEDCT_US
52388000	SNOMEDCT_US
96335004	SNOMEDCT_US
C0138273	UMLSCUI
C0032950	UMLSCUI
CHEMBL1201231	ChEMBL_ID
DB00860	DRUGBANK_ID
5755	PUBCHEM_CID
535	INN_ID
D011239	MESH_DESCRIPTOR_UI
CHEBI:8378	CHEBI
IV021NXA9J	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0759	SOLUTION	15 mg	ORAL	ANDA	19 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0773	SOLUTION	10 mg	ORAL	ANDA	20 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0777	SOLUTION	20 mg	ORAL	ANDA	20 sections
PrednisoLONE Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1100	SOLUTION	5 mg	ORAL	NDA	17 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-4759	SOLUTION	15 mg	ORAL	ANDA	19 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	11695-1431	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	14 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-166	SOLUTION	5 mg	ORAL	NDA	17 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0759	SOLUTION	15 mg	ORAL	ANDA	19 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0815	SOLUTION	15 mg	ORAL	ANDA	17 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-8815	SOLUTION	15 mg	ORAL	ANDA	17 sections
Sulfacetamide Sodium and Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	21695-186	SOLUTION	2.50 mg	OPHTHALMIC	ANDA	18 sections
Sulfacetamide Sodium and Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	24208-317	SOLUTION/ DROPS	2.30 mg	OPHTHALMIC	ANDA	20 sections
PREDNISOLONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	24208-715	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	15 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42254-102	SOLUTION	15 mg	ORAL	ANDA	11 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42799-812	SOLUTION	10 mg	ORAL	ANDA	17 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42799-813	SOLUTION	20 mg	ORAL	ANDA	17 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42799-815	SOLUTION	15 mg	ORAL	ANDA	17 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42799-816	SOLUTION	25 mg	ORAL	ANDA	17 sections
Prednisolone Sodium Phosphate Oral Solution	HUMAN PRESCRIPTION DRUG LABEL	1	44523-182	SOLUTION	25 mg	ORAL	ANDA	15 sections
Prednisolone Sodium Phosphate Oral Solution	HUMAN PRESCRIPTION DRUG LABEL	1	44523-182	SOLUTION	25 mg	ORAL	ANDA	15 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0955	SOLUTION	15 mg	ORAL	ANDA	10 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1582	SOLUTION	15 mg	ORAL	ANDA	19 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0759	SOLUTION	15 mg	ORAL	ANDA	19 sections
prednisolone sodium phosphateODT	Human Prescription Drug Label	1	50742-383	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	NDA AUTHORIZED GENERIC	24 sections
prednisolone sodium phosphateODT	Human Prescription Drug Label	1	50742-384	TABLET, ORALLY DISINTEGRATING	15 mg	ORAL	NDA AUTHORIZED GENERIC	24 sections
prednisolone sodium phosphateODT	Human Prescription Drug Label	1	50742-385	TABLET, ORALLY DISINTEGRATING	30 mg	ORAL	NDA AUTHORIZED GENERIC	24 sections
Sulfacetamide Sodium and Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	53002-8690	SOLUTION/ DROPS	2.30 mg	OPHTHALMIC	ANDA	19 sections
Prednisolone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5242	SOLUTION	15 mg	ORAL	ANDA	11 sections
OrapredODT	Human Prescription Drug Label	1	59212-700	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	NDA	25 sections
OrapredODT	Human Prescription Drug Label	1	59212-701	TABLET, ORALLY DISINTEGRATING	15 mg	ORAL	NDA	25 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

prednisolone sodium phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: